{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:11Z","timestamp":1792601591847,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer-related anorexia-cachexia syndrome (CACS) is a debilitating condition afflicting up to 80% of advanced-stage cancer patients. Characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, CACS significantly compromises patients\u2019 quality of life and treatment outcomes. This comprehensive review navigates through its intricate physiopathology, elucidating its stages and diagnostic methodologies. CACS manifests in three distinct stages: pre-cachexia, established cachexia, and refractory cachexia. Early detection is pivotal for effective intervention and is facilitated by screening tools, complemented by nutritional assessments and professional evaluations. The diagnostic process unravels the complex interplay of metabolic dysregulation and tumor-induced factors contributing to CACS. Management strategies, tailored to individual patient profiles, encompass a spectrum of nutritional interventions. These include dietary counseling, oral nutritional supplements, and, when necessary, enteral nutrition and a judicious use of parenteral nutrition. Specific recommendations for caloric intake, protein requirements, and essential nutrients address the unique challenges posed by CACS. While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient\u2019s condition.<\/jats:p>","DOI":"10.1007\/s12094-024-03502-8","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T07:01:54Z","timestamp":1717225314000},"page":"2866-2876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-8989","authenticated-orcid":false,"given":"Ainara","family":"Soria Rivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Escobar \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blasco Cordellat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem Tarruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Molina Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Motilla de la C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa","family":"del Mar Mu\u00f1oz S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zafra Poves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Beato Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Cabez\u00f3n Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"issue":"5","key":"3502_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3502_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s JM, Busquets S, Stemmler B, L\u00f3pez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754\u201362. https:\/\/doi.org\/10.1038\/nrc3829.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3502_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc927","volume":"2","author":"MJ Tisdale","year":"2002","unstructured":"Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862\u201371. https:\/\/doi.org\/10.1038\/nrc927.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3502_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/apm.2018.08.07","volume":"8","author":"R Dev","year":"2019","unstructured":"Dev R. Measuring cachexia-diagnostic criteria. Ann Palliat Med. 2019;8(1):24\u201332. https:\/\/doi.org\/10.21037\/apm.2018.08.07.","journal-title":"Ann Palliat Med"},{"issue":"3","key":"3502_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.critrevonc.2013.07.015","volume":"88","author":"A Tuca","year":"2013","unstructured":"Tuca A, Jimenez-Fonseca P, Gasc\u00f3n P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88(3):625\u201336. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.015.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3502_CR6","doi-asserted-by":"publisher","first-page":"111271","DOI":"10.1016\/j.nut.2021.111271","volume":"90","author":"EVM Wiegert","year":"2021","unstructured":"Wiegert EVM, de Oliveira LC, Calixto-Lima L, Chaves GV, Silva Lopes MS, Peres WAF. New cancer cachexia staging system for use in clinical practice. Nutrition. 2021;90:111271. https:\/\/doi.org\/10.1016\/j.nut.2021.111271.","journal-title":"Nutrition"},{"key":"3502_CR7","doi-asserted-by":"publisher","unstructured":"Llovera M, Garc\u00eda-Mart\u00ednez C, Agell N, F J L\u00f3pez-Soriano FJ, J M Argil\u00e9s JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun. 1997;230(2):238\u201341. https:\/\/doi.org\/10.1006\/bbrc.1996.5827.","DOI":"10.1006\/bbrc.1996.5827"},{"issue":"1","key":"3502_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.urology.2006.09.039","volume":"69","author":"K Kuroda","year":"2007","unstructured":"Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 2007;69(1):113\u20137. https:\/\/doi.org\/10.1016\/j.urology.2006.09.039.","journal-title":"Urology"},{"key":"3502_CR9","doi-asserted-by":"publisher","unstructured":"Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol. 1995;13(10):2600\u20135. https:\/\/doi.org\/10.1200\/JCO.1995.13.10.2600.","DOI":"10.1200\/JCO.1995.13.10.2600"},{"issue":"3","key":"3502_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1172\/JCI20174","volume":"114","author":"S Acharyya","year":"2004","unstructured":"Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004;114(3):370\u20138. https:\/\/doi.org\/10.1172\/JCI20174.","journal-title":"J Clin Invest"},{"key":"3502_CR11","doi-asserted-by":"publisher","unstructured":"Quint\u00e1s-Cardama A, Verstovsek S. Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0284.","DOI":"10.1158\/1078-0432.CCR-12-0284"},{"key":"3502_CR12","doi-asserted-by":"publisher","first-page":"722652","DOI":"10.3389\/fonc.2021.722652","volume":"11","author":"PK Chiang","year":"2021","unstructured":"Chiang PK, Tsai WK, Chiu AW, Lin JB, Yang FY, Lee J. Muscle loss during androgen deprivation therapy is associated with higher risk of non-cancer mortality in high-risk prostate cancer. Front Oncol. 2021;11:722652. https:\/\/doi.org\/10.3389\/fonc.2021.722652.","journal-title":"Front Oncol"},{"key":"3502_CR13","doi-asserted-by":"publisher","unstructured":"Colomba E, Alves Costa Silva C, Le Teuff G, Elmawieh J, Afonso D, Benchimol-Zouari A, et al. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. J Cachexia Sarcopenia Muscle. 2022;13(5):2405\u20132416. https:\/\/doi.org\/10.1002\/jcsm.13021.","DOI":"10.1002\/jcsm.13021"},{"key":"3502_CR14","doi-asserted-by":"publisher","unstructured":"Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open. 2021;6(3):100092. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100092","DOI":"10.1016\/j.esmoop.2021.100092"},{"issue":"21","key":"3502_CR15","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438\u201353. https:\/\/doi.org\/10.1200\/JCO.20.00611.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3502_CR16","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","volume":"40","author":"M Muscaritoli","year":"2021","unstructured":"Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898\u2013913. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.005.","journal-title":"Clin Nutr"},{"key":"3502_CR17","doi-asserted-by":"publisher","unstructured":"Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22(3):321\u201336. https:\/\/doi.org\/10.1016\/s0261-5614(02)00214-5","DOI":"10.1016\/s0261-5614(02)00214-5"},{"issue":"5","key":"3502_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1079\/bjn20041258","volume":"92","author":"RJ Stratton","year":"2004","unstructured":"Stratton RJ, Hackston A, Longmore D, Dixon R, Price S, Stroud M, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the \u2018malnutrition universal screening tool\u2019 (\u2018MUST\u2019) for adults. Br J Nutr. 2004;92(5):799\u2013808. https:\/\/doi.org\/10.1079\/bjn20041258.","journal-title":"Br J Nutr"},{"issue":"11","key":"3502_CR19","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s00520-006-0070-5","volume":"14","author":"E Isenring","year":"2006","unstructured":"Isenring E, Cross G, Daniels L, Kellett E, Koczwara B. Validity of the malnutrition screening tool as an effective predictor of nutritional risk in oncology outpatients receiving chemotherapy. Support Care Cancer. 2006;14(11):1152\u20136. https:\/\/doi.org\/10.1007\/s00520-006-0070-5.","journal-title":"Support Care Cancer"},{"issue":"9","key":"3502_CR20","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1007\/s00520-016-3196-0","volume":"24","author":"J Abbott","year":"2016","unstructured":"Abbott J, Teleni L, McKavanagh D, Watson J, McCarthy AL, Isenring E. Patient-Generated subjective global assessment short form (PG-SGA SF) is a valid screening tool in chemotherapy outpatients. Support Care Cancer. 2016;24(9):3883\u20137. https:\/\/doi.org\/10.1007\/s00520-016-3196-0.","journal-title":"Support Care Cancer"},{"key":"3502_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nut.2016.07.015","volume":"33","author":"L Arribas","year":"2017","unstructured":"Arribas L, Hurt\u00f3s L, Sendr\u00f3s MJ, Peir\u00f3 I, Salleras N, Fort E, et al. NUTRISCORE: a new nutritional screening tool for oncological outpatients. Nutrition. 2017;33:297\u2013303. https:\/\/doi.org\/10.1016\/j.nut.2016.07.015.","journal-title":"Nutrition"},{"key":"3502_CR22","doi-asserted-by":"publisher","unstructured":"Escobar Y, Ramchandani A, Salgado M, Castillo-Trujillo A, Mart\u00ednez de Castro E, Diaz de Corcuera I, et al. What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study. Clin Transl Oncol 2023;25:3479\u201391. https:\/\/doi.org\/10.1007\/s12094-023-03212-7","DOI":"10.1007\/s12094-023-03212-7"},{"issue":"5","key":"3502_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12094-017-1757-4","volume":"20","author":"JA Virizuela","year":"2018","unstructured":"Virizuela JA, Camblor-\u00c1lvarez M, Luengo-P\u00e9rez LM, Grande E, \u00c1lvarez-Hern\u00e1ndez J, Sendr\u00f3s-Madro\u00f1o MJ, et al. Nutritional support and parenteral nutrition in cancer patients: an expert consensus report. Clin Transl Oncol. 2018;20(5):619\u201329. https:\/\/doi.org\/10.1007\/s12094-017-1757-4.","journal-title":"Clin Transl Oncol"},{"key":"3502_CR24","doi-asserted-by":"publisher","unstructured":"Alderman B, Lindsey A, Amano K, Bouleuc C, Davis M, Lister-Flynn S, et al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion\/guidance on the use of clinically assisted nutrition in patients. Advanced cancer. Supportive Care in Cancer. 2022;30(4):2983\u201392. https:\/\/doi.org\/10.1007\/s00520-021-06613-y.","DOI":"10.1007\/s00520-021-06613-y."},{"key":"3502_CR25","doi-asserted-by":"publisher","unstructured":"Garg S, Yoo J, Winquist E. Nutritional support for head and neck & cancer patients receiving radiotherapy: a systematic review. Support Care Cancer. 2010;18(6):667\u201377.44. https:\/\/doi.org\/10.1007\/s00520-009-0686-3.","DOI":"10.1007\/s00520-009-0686-3"},{"issue":"5","key":"3502_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.clnu.2013.06.012","volume":"32","author":"JA Langius","year":"2013","unstructured":"Langius JA, Zandbergen MC, Eerenstein SE, et al. Effect of nutritional interventions on nutritional status, quality of life and mortality inpatients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. Clin Nutr. 2013;32(5):671\u20138. https:\/\/doi.org\/10.1016\/j.clnu.2013.06.012.","journal-title":"Clin Nutr"},{"key":"3502_CR27","doi-asserted-by":"publisher","unstructured":"JLC, Leong LP, Lim SL. Nutrition intervention approaches to reduce malnutrition in oncology patients: a systematic review. Support Care Cancer. 2016;24(1):469\u201380. https:\/\/doi.org\/10.1007\/s00520-015-2958-4.","DOI":"10.1007\/s00520-015-2958-4."},{"issue":"5","key":"3502_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/annonc\/mdy114","volume":"29","author":"MAE Van der Schueren","year":"2018","unstructured":"Van der Schueren MAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018;29(5):1141\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdy114.","journal-title":"Ann Oncol"},{"key":"3502_CR29","doi-asserted-by":"publisher","unstructured":"Van der Meij BS, van Bokhorst-de van der Schueren MA, Langius JA, Brouwer IA, van Leeuwen PAM. N-3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation. Am J Clin Nutr. 2011;94(5):1248\u201365. https:\/\/doi.org\/10.3945\/ajcn.110.007377.","DOI":"10.3945\/ajcn.110.007377."},{"key":"3502_CR30","doi-asserted-by":"publisher","unstructured":"Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, anomega-3 fatty acid fromfish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007;1:CD004597. https:\/\/doi.org\/10.1002\/14651858.CD004597.pub2.","DOI":"10.1002\/14651858.CD004597.pub2."},{"issue":"3","key":"3502_CR31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00520-019-05145-w","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Bruera E, Arends J, Walsh D, Strasser F, Isenring E, et al. Enteral and parenteral nutrition in cancer, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Support Care Cancer. 2020;28(3):979\u20131010. https:\/\/doi.org\/10.1007\/s00520-019-05145-w.","journal-title":"Support Care Cancer"},{"issue":"1","key":"3502_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3978\/j.issn.2224-5820.2016.01.05","volume":"5","author":"P Cotogni","year":"2016","unstructured":"Cotogni P. Enteral versus parenteral nutrition in cancer patients: evidences and controversies. Ann Palliat Med. 2016;5(1):42\u20139. https:\/\/doi.org\/10.3978\/j.issn.2224-5820.2016.01.05.","journal-title":"Ann Palliat Med"},{"issue":"11","key":"3502_CR33","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/ejcn.2016.96","volume":"70","author":"SA Purcell","year":"2016","unstructured":"Purcell SA, Elliott SA, Baracos VE, Chu QS, Prado CM. Key determinants of energy expenditure in cancer and implications for clinical practice. Eur J Clin Nutr. 2016;70(11):1230\u20138. https:\/\/doi.org\/10.1038\/ejcn.2016.96.","journal-title":"Eur J Clin Nutr"},{"issue":"14","key":"3502_CR34","doi-asserted-by":"publisher","first-page":"24009","DOI":"10.18632\/oncotarget.15103","volume":"8","author":"A Gangadharan","year":"2017","unstructured":"Gangadharan A, Choi SE, Hassan A, Ayoub NM, Durante G, Balwani S, et al. Protein calorie malnutrition, nutritional intervention and personalized cancer care. Oncotarget. 2017;8(14):24009\u201330. https:\/\/doi.org\/10.18632\/oncotarget.15103.","journal-title":"Oncotarget"},{"issue":"9","key":"3502_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/15353702221087962","volume":"247","author":"M Hegde","year":"2022","unstructured":"Hegde M, Daimary UD, Girisa S, Kumar A, Kunnumakkara AB. Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia. Exp Biol Med (Maywood). 2022;247(9):713\u201333. https:\/\/doi.org\/10.1177\/15353702221087962.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"3502_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clnu.2011.05.008","volume":"30","author":"NE Deutz","year":"2011","unstructured":"Deutz NE, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr (Edinb). 2011;30(6):759\u201368. https:\/\/doi.org\/10.1016\/j.clnu.2011.05.008.","journal-title":"Clin Nutr (Edinb)"},{"issue":"2","key":"3502_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/bjs.1800760215","volume":"76","author":"DC Hunter","year":"1989","unstructured":"Hunter DC, Weintraub M, Blackburn GL, Bistrian BR. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg. 1989;76(2):149\u201353. https:\/\/doi.org\/10.1002\/bjs.1800760215.","journal-title":"Br J Surg"},{"issue":"3","key":"3502_CR38","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/jcsm.12952","volume":"13","author":"CM Prado","year":"2022","unstructured":"Prado CM, Orsso CE, Pereira SL, Atherton PJ, Deutz NEP. Effects of \u03b2-hydroxy \u03b2-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review. J Cachexia Sarcopenia Muscle. 2022;13(3):1623\u201341. https:\/\/doi.org\/10.1002\/jcsm.12952.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"3502_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/02601060231153428","volume":"29","author":"K Lee","year":"2023","unstructured":"Lee K, Blanton C. The effect of branched-chain amino acid supplementation on cancer treatment. Nutr Health. 2023;29(4):621\u201335. https:\/\/doi.org\/10.1177\/02601060231153428.","journal-title":"Nutr Health"},{"issue":"2","key":"3502_CR40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/jcsm.12525","volume":"11","author":"CM Prado","year":"2020","unstructured":"Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):366\u201380. https:\/\/doi.org\/10.1002\/jcsm.12525.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"3502_CR41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/SLA.0b013e318252edf8","volume":"255","author":"K Marimuthu","year":"2012","unstructured":"Marimuthu K, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of the effect of combinations of immune modulating nutrients on outcome in patients undergoing major open gastrointestinal surgery. Ann Surg. 2012;255(6):1060\u20138. https:\/\/doi.org\/10.1097\/SLA.0b013e318252edf8.","journal-title":"Ann Surg"},{"key":"3502_CR42","doi-asserted-by":"publisher","unstructured":"de Aguiar Pastore Silva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and\/or radiotherapy: a systematic review. Clin Nutr (Edinb) 2015;34(3):359\u201366. https:\/\/doi.org\/10.1016\/j.clnu.2014.11.005.","DOI":"10.1016\/j.clnu.2014.11.005."},{"key":"3502_CR43","doi-asserted-by":"publisher","unstructured":"Sanchez-Lara K, Turcott JG, Juarez-Hernandez E, Nu\u00f1ez-Valencia C, Villanueva G, Guevara P, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr(Edinb) 2014;33(6):1017\u201323. https:\/\/doi.org\/10.1016\/j.clnu.2014.03.006.","DOI":"10.1016\/j.clnu.2014.03.006."},{"issue":"1","key":"3502_CR44","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1038\/s41598-021-82120-8","volume":"11","author":"DC Currow","year":"2021","unstructured":"Currow DC, Glare P, Louw S, Martin P, Clark K, Fazekas B, et al. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep. 2021;11(1):2421. https:\/\/doi.org\/10.1038\/s41598-021-82120-8.","journal-title":"Sci Rep"},{"issue":"6410","key":"3502_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/bmj.288.6410.27","volume":"288","author":"JC Willox","year":"1984","unstructured":"Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed). 1984;288(6410):27. https:\/\/doi.org\/10.1136\/bmj.288.6410.27.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"3502_CR46","doi-asserted-by":"publisher","unstructured":"Ruiz Garcia V, L\u00f3pez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013(3):CD004310. https:\/\/doi.org\/10.1002\/14651858.CD004310.pub3.","DOI":"10.1002\/14651858.CD004310.pub3"},{"issue":"8","key":"3502_CR47","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1517\/14656560902960162","volume":"10","author":"C Madeddu","year":"2009","unstructured":"Madeddu C, Macci\u00f2 A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009;10(8):1359\u201366. https:\/\/doi.org\/10.1517\/14656560902960162.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"3502_CR48","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1200\/JCO.1993.11.4.762","volume":"11","author":"CL Loprinzi","year":"1993","unstructured":"Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and\/or cachexia. J Clin Oncol. 1993;11(4):762\u20137. https:\/\/doi.org\/10.1200\/JCO.1993.11.4.762.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3502_CR49","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/jcsm.12295","volume":"9","author":"TJ Wright","year":"2018","unstructured":"Wright TJ, Dillon EL, Durham WJ, Chamberlain A, Randolph KM, Danesi C, et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J Cachexia Sarcopenia Muscle. 2018;9(3):482\u201396. https:\/\/doi.org\/10.1002\/jcsm.12295.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"3502_CR50","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00520-016-3560-0","volume":"25","author":"Y Bai","year":"2017","unstructured":"Bai Y, Hu Y, Zhao Y, Yu X, Xu J, Hua Z, et al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer. 2017;25(5):1651\u20139. https:\/\/doi.org\/10.1007\/s00520-016-3560-0.","journal-title":"Support Care Cancer"},{"issue":"7","key":"3502_CR51","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.22.01632","volume":"41","author":"J Hardy","year":"2023","unstructured":"Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). J Clin Oncol. 2023;41(7):1444\u201352. https:\/\/doi.org\/10.1200\/JCO.22.01632.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3502_CR52","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/1097-0142(19900615)65:12<2657::aid-cncr2820651210>3.0.co;2-s","volume":"65","author":"CG Kardinal","year":"1990","unstructured":"Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and\/or cachexia. Cancer. 1990;65(12):2657\u201362. https:\/\/doi.org\/10.1002\/1097-0142(19900615)65:12%3c2657::aid-cncr2820651210%3e3.0.co;2-s.","journal-title":"Cancer"},{"issue":"6","key":"3502_CR53","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.1994.12.6.1126","volume":"12","author":"CL Loprinzi","year":"1994","unstructured":"Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994;12(6):1126\u20139. https:\/\/doi.org\/10.1200\/JCO.1994.12.6.1126.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3502_CR54","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/JCO.2012.43.6766","volume":"31","author":"E Del Fabbro","year":"2013","unstructured":"Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31(10):1271\u20136. https:\/\/doi.org\/10.1200\/JCO.2012.43.6766.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3502_CR55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","volume":"52","author":"TS Solheim","year":"2013","unstructured":"Solheim TS, Fearon KC, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol. 2013;52(1):6\u201317. https:\/\/doi.org\/10.3109\/0284186X.2012.724536.","journal-title":"Acta Oncol"},{"issue":"14","key":"3502_CR56","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol. 2023;41(14):2617\u201327. https:\/\/doi.org\/10.1200\/JCO.22.01997.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3502_CR57","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","volume":"15","author":"S Yennurajalingam","year":"2012","unstructured":"Yennurajalingam S, Willey JS, Palmer JL, Allo J, Del Fabbro E, Cohen EN, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med. 2012;15(10):1059\u201364. https:\/\/doi.org\/10.1089\/jpm.2012.0146.","journal-title":"J Palliat Med"},{"issue":"2","key":"3502_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","volume":"68","author":"A Jatoi","year":"2010","unstructured":"Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68(2):234\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2009.06.020.","journal-title":"Lung Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03502-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T06:04:21Z","timestamp":1728626661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3502"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03502-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the given and family names of all the authors.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ASR has participated in conferences for MSD, BMS, Novartis, Pierre Fabre, Regeneron, Merck Serono, Immunocore, Sanofi Aventis and Viatris; has participated in advisories for MSD, MS, Novartis, Immunocore, Regeneron; and he is on the steering committee of an IO biotech trial. LCG reports advisory board, speaker, personal fees from Roche; speaker, personal fees from Astra Zeneca, BMS, Merck Serono and MSD; advisory board from Eisai and speaker from Kyowa Kirin, Grunenthal and Pfizer. MMC, ABC, CBZ, YEA, MMT, KMM, MMS, MZP have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Compliance with ethical standards: The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}